论文部分内容阅读
目的 通过测定深静脉血栓(DVT)患者活化部分凝血活酶时间(APTT)和抗因子Xa活性,分析两天指标在检测低分子肝素(LMWH)治疗深静脉血栓患者效果中的意义.方法 选择规律使用LMWH的深静脉血栓患者56例,分别检测患者用药前后的APTT和抗因子Xa活性,同时对二者进行应用分析.结果 APTT在LMWH使用前为(41.1±8.1)s,使用后为(45.5±7.3)s;抗因子Xa在LMWH使用前为(0.03±0.02)IU/mL,使用后为(0.52±0.07)IU/mL;APTT与抗因子Xa使用后都较使用前升高,且差异有统计学意义(t=-12.199、46.494,P<0.05).APTT监测与抗因子Xa监测的结果相比较,落在目标剂量范围内(APTT为1.5~2.5倍参考值上限,为64.5~107.5 s;抗因子Xa为0.5~1.0 IU/mL)的患者,以抗因子Xa法所测得结果比例更高.结论 DVT患者使用LMWH抗凝时,通过检测抗因子Xa活性调整用药剂量比APTT检测更有利于临床对患者使用LMWH效果的监测.临床上经验性使用LMWH后抗因子Xa活性基本在安全范围内,提示临床的经验性用药具有较好的安全性.“,”Objective To evaluate the effect of low-molecular-weight heparin (LMWH) in the treatment of patients with deep venous thrombosis (DVT) by measurement of activated partial thromboplastin time (APTT) and anti-factor Xa activity.Methods A total of 56 patients with DVT which had been treated with LMWH were selected.Levels of APTT and anti-factor Xa were detected and compared before and after the treatment in the two groups.Results APTT values of patients before and after LMWH treatment were (41.1±8.1)s and (45.5±7.3)s respectively.And anti-factor Xa before and after the treatment were (0.03±0.02)IU/mL and (0.52±0.07)IU/mL,differences were statistically significance (P<0.05).Compared with APTT,the rate of patients within the scope of the target dos was significantly higher by the method of anti-factor Xa (APTT:64.5-107.5 s;anti-factor Xa:0.5-1.0 IU/mL) (P<0.05).Conclusion Monitoring anti-factor Xa activity has more advantages than APTT in patients with DVT after using LMWH.And anti-factor Xa has good security that is tested by the clinical experience administration.